Eli Lilly Buys Verve Therapeutics for $1.3 Billion to Transform Cardiovascular Care

Eli Lilly & Co. has announced a major acquisition, purchasing Verve Therapeutics, a firm specializing in gene editing, for $1.3 billion. This transaction includes a substantial cash payment of $1 billion at $10.50 per share, along with an additional contingent value right (CVR) of $3 per share. The total potential value of this deal amounts to approximately ₹11,000 crore.

Verve Therapeutics, which is publicly traded on Nasdaq, is dedicated to the development of innovative gene-editing therapies, particularly focused on single-dose solutions for atherosclerotic cardiovascular disease (ASCVD). The firm's leading initiative, VERVE-102, is designed to target and silence the PCSK9 gene. This gene is significant due to its role in the regulation of cholesterol levels. VERVE-102 is currently undergoing Phase 1b clinical trials and has already received Fast Track designation from the U.S. Food and Drug Administration (FDA).

This strategic acquisition is expected to bolster Lilly's capabilities and presence in the fields of cardiometabolic diseases and genetic medicine. By utilizing Verve's advanced technology, Lilly aims to create groundbreaking treatments that offer long-term cardiovascular risk reduction through a single administration. This move is in line with the company's objectives to revolutionize how cardiovascular issues are treated, moving away from traditional therapies toward more innovative and long-lasting solutions.

In addition to VERVE-102, Verve's research pipeline includes other promising candidates. VERVE-201 is being developed to target the ANGPTL3 gene, which is involved in the reduction of triglyceride levels. Another candidate, VERVE-301, focuses on addressing lipoprotein(a), an established risk factor for heart disease and stroke.

Eli Lilly plans to complete this acquisition by the third quarter of 2025. The company intends to acquire any shares not tendered in the initial offer through a subsequent merger. This acquisition is part of Lilly’s broader strategy to diversify its portfolio and establish a strong foothold in gene-editing solutions, particularly for cardiovascular health. By doing so, Lilly aims to expand its impact and leadership in the gene-editing field, providing innovative and effective treatments for cardiovascular diseases.

Overall, this acquisition reflects Eli Lilly's commitment to advancing healthcare by integrating cutting-edge gene-editing techniques into its treatment offerings. The collaboration with Verve Therapeutics positions Lilly to explore new frontiers in medical treatments, potentially transforming the landscape of cardiovascular health and offering new hope to patients worldwide.